A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

@article{Horn2011API,
  title={A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.},
  author={Lindsay A. Horn and Zhiguo Zhao and Alan N. Sandler and David L. Johnson and Yu Shyr and Steven N. Wolff and Russell F Devore and Janessa L. Laskin},
  journal={Clinical lung cancer},
  year={2011},
  volume={12 3},
  pages={
          161-5
        }
}
OBJECTIVES Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings. METHODS Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function… CONTINUE READING
BETA